BMRN vs. SRPT, TEVA, MYOK, RETA, MRTX, BIIB, ALNY, INCY, NBIX, and UTHR
Should you be buying BioMarin Pharmaceutical stock or one of its competitors? The main competitors of BioMarin Pharmaceutical include Sarepta Therapeutics (SRPT), Teva Pharmaceutical Industries (TEVA), MyoKardia (MYOK), Reata Pharmaceuticals (RETA), Mirati Therapeutics (MRTX), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), Neurocrine Biosciences (NBIX), and United Therapeutics (UTHR). These companies are all part of the "medical" sector.
BioMarin Pharmaceutical (NASDAQ:BMRN) and Sarepta Therapeutics (NASDAQ:SRPT) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.
BioMarin Pharmaceutical currently has a consensus price target of $102.00, indicating a potential upside of 20.58%. Sarepta Therapeutics has a consensus price target of $187.72, indicating a potential upside of 30.15%. Given Sarepta Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sarepta Therapeutics is more favorable than BioMarin Pharmaceutical.
BioMarin Pharmaceutical has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.
98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are held by institutional investors. 1.9% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 7.7% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, BioMarin Pharmaceutical had 18 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 30 mentions for BioMarin Pharmaceutical and 12 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.82 beat BioMarin Pharmaceutical's score of 0.63 indicating that Sarepta Therapeutics is being referred to more favorably in the news media.
BioMarin Pharmaceutical has a net margin of 8.31% compared to Sarepta Therapeutics' net margin of 1.20%. BioMarin Pharmaceutical's return on equity of 5.34% beat Sarepta Therapeutics' return on equity.
BioMarin Pharmaceutical received 98 more outperform votes than Sarepta Therapeutics when rated by MarketBeat users. However, 75.34% of users gave Sarepta Therapeutics an outperform vote while only 74.65% of users gave BioMarin Pharmaceutical an outperform vote.
BioMarin Pharmaceutical has higher revenue and earnings than Sarepta Therapeutics. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
BioMarin Pharmaceutical and Sarepta Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get BioMarin Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioMarin Pharmaceutical Competitors List
Related Companies and Tools
